Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
LifeMD, Inc. (LFMD)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
$2.29-6.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LFMD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Utilize $30M credit facility for growth initiatives | The company secured a $30M credit facility to support growth. | Intact | Credit facility remains unused or misused, failing to support growth | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making growth business, with a healthcare sector backdrop that has recently improved. Its long-term thesis remains in a watch state: recent performance has lagged its industry cohort, while management’s main goals show mixed progress.
LFMD is described as cheap versus peers, but the valuation model has low confidence. The expectations gap is negative, which points to limited confidence in the current outlook; the evidence does not support a clearer estimate of what the market assumes.
Near term, revenue growth and profitability remain uncertain: management cut 2026 revenue guidance and shifted its adjusted EBITDA outlook from a positive range to a loss-to-breakeven range, though quarterly adjusted EBITDA losses narrowed from Q1 to Q2. Partnerships and product launches are ongoing, but disclosed evidence on their revenue contribution is thin.
A favorable shift would require guidance to improve after the recent reduction, alongside continued progress toward positive adjusted EBITDA in the second half of 2026. The thesis also depends on whether healthcare-sector momentum persists; weaker employment data could increase recession concerns and pressure cyclical healthcare names.
Over the next 1 to 3 years, the thesis rests on whether LFMD can translate its partnerships and sector support into consistent growth and better operating results. Execution is mixed, risk is high, and the evidence remains limited. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A new CTO appointment supports technology and growth initiatives. |
| Improving |
| CTO departure or failure to advance technology growth initiatives |
Qualitative: CTO appointed Jun 2026; AT&T partnership Sep 2026 New CTO appointed June 2026. AT&T partnership secured September 2026. Q2 2026 earnings beat expectations. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to $220M-$230M in fiscal 2026 | A primary condition in LifeMD, Inc.'s published investment case. The stated target is >= $220 million and <= $230 million. | Broken | Annual revenue falls below $220 million in FY26 | Revenue: $47.281M FY2026-Q2; GAAP. Published target: >= $220 million and <= $230 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 5, 202647,281,085 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.52 → $-0.09 · observed estimates
$0.26B → $0.24B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.52 | $260,901,120 | 2 / 8 |
| 2026-07-25 | $0.07 | $260,901,175 | 3 / 6 |
| 2026-07-26 | $0.52 | $260,901,120 | 2 / 8 |
| 2026-07-27 | $0.07 | $260,894,925 | 3 / 6 |
| 2026-07-28 | $0.52 | $260,901,120 | 2 / 8 |
| 2026-07-29 | $0.52 | $260,901,120 | 2 / 8 |
| 2026-07-30 | $0.52 | $260,901,120 | 2 / 8 |
| 2026-07-31 | $0.52 | $260,901,120 | 2 / 8 |
| 2026-08-01 | $0.07 | $260,894,925 | 3 / 6 |
| 2026-08-02 | $0.52 | $260,901,120 | 2 / 8 |
| 2026-08-03 | $0.52 | $260,901,120 | 2 / 8 |
| 2026-08-04 | $0.52 | $260,901,120 | 2 / 8 |
| 2026-08-05 | $0.07 | $260,894,925 | 3 / 6 |
| 2026-08-06 | $0.07 | $260,894,925 | 3 / 6 |
| 2026-08-07 | $-0.00 | $255,957,125 | 3 / 6 |
| 2026-08-08 | $0.48 | $249,382,000 | 2 / 8 |
| 2026-08-09 | $0.48 | $249,382,000 | 2 / 8 |
| 2026-08-10 | $0.48 | $249,382,000 | 2 / 8 |
| 2026-08-12 | $-0.00 | $255,957,125 | 3 / 6 |
| 2026-08-13 | $-0.00 | $255,957,125 | 3 / 6 |
| 2026-08-14 | $-0.00 | $255,957,125 | 3 / 6 |
| 2026-08-15 | $-0.00 | $255,957,125 | 3 / 6 |
| 2026-08-16 | $-0.00 | $255,957,125 | 3 / 6 |
| 2026-08-17 | $-0.00 | $255,957,125 | 3 / 6 |
| 2026-08-18 | $-0.00 | $255,957,125 | 3 / 6 |
| 2026-08-19 | $-0.00 | $255,957,125 | 3 / 6 |
| 2026-08-20 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-08-21 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-08-22 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-08-23 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-08-24 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-08-25 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-08-26 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-08-27 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-08-28 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-08-29 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-08-30 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-08-31 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-09-01 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-09-02 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-09-03 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-09-04 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-09-05 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-09-06 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-09-07 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-09-08 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-09-09 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-09-10 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-09-11 | $-0.05 | $245,007,000 | 3 / 6 |
| 2026-09-12 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-13 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-14 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-15 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-16 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-17 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-18 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-19 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-20 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-21 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-22 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-23 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-24 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-25 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-26 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-27 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-28 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-29 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-09-30 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-01 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-02 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-03 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-04 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-05 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-06 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-07 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-08 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-09 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-10 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-11 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-12 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-13 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-14 | $-0.09 | $245,094,500 | 4 / 6 |
| 2026-10-15 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-16 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-17 | $-0.09 | $245,094,500 | 3 / 6 |
| 2026-10-18 | $-0.09 | $244,994,500 | 3 / 6 |
| 2026-10-19 | $-0.09 | $244,994,500 | 3 / 6 |
| 2026-10-20 | $-0.09 | $244,994,500 | 3 / 6 |
| 2026-10-21 | $-0.09 | $244,994,500 | 3 / 6 |
| 2026-10-22 | $-0.09 | $244,994,500 | 3 / 6 |
| 2026-10-23 | $-0.09 | $244,994,500 | 3 / 6 |
| 2026-10-24 | $-0.09 | $244,994,500 | 3 / 6 |
| 2026-10-25 | $-0.09 | $244,994,500 | 3 / 6 |
| 2026-10-26 | $-0.09 | $244,994,500 | 3 / 6 |
| 2026-10-27 | $-0.09 | $244,994,500 | 3 / 6 |
| 2026-10-28 | $-0.09 | $244,988,250 | 3 / 6 |
| 2026-10-29 | $-0.09 | $244,988,250 | 3 / 6 |
| 2026-10-30 | $-0.09 | $244,988,250 | 3 / 6 |
| 2026-10-31 | $-0.09 | $244,988,250 | 3 / 6 |
| 2026-11-01 | $-0.09 | $244,988,250 | 3 / 6 |
| 2026-11-02 | $-0.09 | $244,988,250 | 3 / 6 |
| 2026-11-03 | $-0.09 | $244,988,250 | 3 / 6 |
| 2026-11-04 | $-0.09 | $244,988,250 | 3 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.